Nicorandil, chemically known as N-(2-hydroxyethyl)nicotinamide nitrate with the molecular formula C8H9N3O4, is an ATP-sensitive potassium channel opener for clinical use. Clinical studies have confirmed that nicorandil is indicated for all types of angina pectoris, including exertional angina and spastic angina, and that it significantly reduces the risk of cardiovascular events and improves prognosis.
Uses: Anti-anginal agent. It has the effect of selectively dilating coronary arteries, continuously increasing coronary flow and inhibiting coronary spasm. Used for all kinds of angina pectoris.
Development: Nicorandil was successfully manufactured by Chugai Pharmaceutical and Mitsubishi Oil & Chemical in 1978, and was used in clinical research in 1981, and was given the international generic name Nicorandil in 1982. It reached the practical stage and was marketed in Japan in early 1984. Currently marketed under the following trade names: Ikorel (in the UK, Australia and most of Europe), Dancor (Switzerland), Zynicor (in India), Aprior (Philippines), Sigmart (in Japan, Korea and Taiwan), Xindipine (China - Xi'an Hanfeng).
Pharmacological effects: Anti-anginal agent. It is a nitrate compound, which has the effect of preventing intracellular calcium ion free, increasing the permeability of cell membrane to potassium ion, dilating coronary vessels, continuously increasing coronary blood flow and inhibiting coronary artery spasm, and does not affect blood pressure, heart rate, myocardial contractility and myocardial oxygen consumption when dilating coronary vessels. This product also has the effect of inhibiting platelet aggregation to prevent thrombosis.